About Xeptagen S.p.A.
XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.
Latest Xeptagen S.p.A. News
Sep 8, 2017
09:07 EDT 8 Sep 2017 | BioPortfolio Reports Summary Xeptagen SpA Xeptagen is a medical device company that discovers molecular markers. The company produces diagnostic kits for the monitoring , detection, and screening of cancerous cells. It develops an optoelectronic biochip for the determination of tumor molecular markers; and conducts research on developing biochips for the simultaneous detection of biomarkersIgM immunecomplexes. Xeptagen uses combinatorial proteomic technology to discover prognostic, predictive and early response tumor markers. The company operates through several medical device and research organizations to develop its products. It performs research for the treatment of liver cancer, colorectal cancer, and prostate cancer. Xeptagen is headquartered in Marghera, Italy. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company XEPTAGEN SpA The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date The report provides detailed description of products in development, technical specification and functions The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio To formulate effective Research Development strategies Develop marketentry and market expansion strategies Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio Note: Some sections may be missing if data is unavailable for the company Related Biotechnology, Pharmaceutical and Healthcare News
Xeptagen S.p.A. Frequently Asked Questions (FAQ)
Who are Xeptagen S.p.A.'s competitors?
Competitors of Xeptagen S.p.A. include AllerQuest, Chemclin, Aviir, Nodality, Predictive Biosciences and 7 more.
Compare Xeptagen S.p.A. to Competitors
StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.
Canary Foundation is a non-profit organization focused on the development of early cancer detection tests within the healthcare sector. The foundation's main offerings include funding and supporting research for the discovery of biomarkers and imaging techniques that facilitate the early diagnosis of solid tumor cancers. Canary Foundation primarily collaborates with research institutions and the healthcare industry to advance early cancer detection technologies. It was founded in 2004 and is based in San Jose, California.
Nodality is a biotechnology company focused on enhancing drug development through its innovative technology. The company offers services and products that provide translational models of disease, drug action, and patient-specific response, primarily for the pharmaceutical industry. Nodality's main offerings include customized services and a product line that aids in the drug discovery and development process. It was founded in 2003 and is based in South San Francisco, California.
Litholink is a healthcare company focused on kidney stone prevention through specialized testing services. The company offers 24-hour urine testing kits and collection services to facilitate the diagnosis and management of kidney stone risk. Litholink primarily serves healthcare providers and patients with a national infrastructure that supports integrated laboratory services. It is based in Chicago, Illinois.
Alerion Biomedical Inc. in San Diego is developing products for the detection, characterization and treatment of disease. The company is developing technologies aimed at studying and managing major diseases including cancer, vascular disorders and hepatobiliary disease. Alerion's latest product line, Fenestra, is revolutionizing the way in vivo imaging is used in basic research and drug development. Founded initially in 1997 as MetaProbe LLC by Research Corporation Technologies and the California Institute of Technology, Alerion Biomedical has grown to encompass a broad range of drug-delivery and medical imaging technologies. Advanced Research Technologies Inc., a Canadian medical device company, acquired substantially all of the imaging technology and product assets of Alerion in March 2006. ART is actively promoting the Fenestra product line.
Viridis' equipment is a disease marker testing platform to be used at point-of-care.